Efficacy of imidacloprid 10%/moxidectin 1% spot-on formulation (Advocate®) in the prevention and treatment of feline aelurostrongylosis

Autor: Georg von Samson-Himmelstjerna, Katrin Blazejak, Lea Heuer, Donato Traversa, Katrin Deuster, Manuela Schnyder, Matthias Pollmeier, Janina McKay-Demeler, Sandra Mangold-Gehring, Claudia Böhm, Holger Schmidt, Angela Di Cesare, Christina Strube, Gabriele Petry, Roland Schaper
Přispěvatelé: University of Zurich, Mangold-Gehring, Sandra
Jazyk: angličtina
Rok vydání: 2020
Předmět:
10078 Institute of Parasitology
Male
Administration
Topical
2405 Parasitology
Aelurostrongylus abstrusus
Cat Diseases
Gastroenterology
0403 veterinary science
chemistry.chemical_compound
Neonicotinoids
0302 clinical medicine
Aelurostrongylosis
600 Technology
Lung
CATS
biology
Animal health
Feline lungworm
04 agricultural and veterinary sciences
Nitro Compounds
Treatment efficacy
Moxidectin
Infectious Diseases
Treatment Outcome
Larva
Female
Macrolides
medicine.medical_specialty
040301 veterinary sciences
Drug Compounding
030231 tropical medicine
610 Medicine & health
Drug Administration Schedule
lcsh:Infectious and parasitic diseases
03 medical and health sciences
Imidacloprid
Internal medicine
parasitic diseases
medicine
Animals
lcsh:RC109-216
600 Technik
Medizin
angewandte Wissenschaften::630 Landwirtschaft::632 Schäden
Krankheiten
Schädlinge an Pflanzen
Strongylida Infections
Life Cycle Stages
Prevention
Treatment
Research
2725 Infectious Diseases
biology.organism_classification
Metastrongyloidea
chemistry
Parasitology
Cats
570 Life sciences
Zdroj: Parasites & Vectors
Parasites & Vectors, Vol 13, Iss 1, Pp 1-10 (2020)
ISSN: 1756-3305
Popis: Background In three randomized, controlled laboratory efficacy studies, the efficacy in the prevention of patent infections of a topical combination of imidacloprid 10%/moxidectin 1% (Advocate® spot-on formulation for cats, Bayer Animal Health GmbH) against larval stages and immature adults of Aelurostrongylus abstrusus, as well as the treatment efficacy of a single or three monthly treatments against adult A. abstrusus, were evaluated. Methods Cats were experimentally inoculated with 300–800 third-stage larvae (L3). Each group comprised 8 animals and the treatment dose was 10 mg/kg bodyweight (bw) imidacloprid and 1 mg/kg bw moxidectin in each study. Prevention of the establishment of patent infections was evaluated by two treatments at a monthly interval at three different time points before and after challenge infection. Curative efficacy was tested by one or three treatments after the onset of patency. Worm counts at necropsy were used for efficacy calculations. Results In Study 1, the control group had a geometric mean (GM) of 28.8 adult nematodes and the single treatment group had a GM of 3.4 (efficacy 88.3%). In Study 2, the control group had a GM of 14.3, the prevention group had a GM of 0 (efficacy 100%), while the treatment group had a GM of 0.1 (efficacy 99.4%). In Study 3, the GM worm burden in the control group was 32.6 compared to 0 in all three prevention groups (efficacy 100% for all of those groups). Conclusions The monthly administration of Advocate® reliably eliminated early larval stages and thereby prevented lung damage from and patent infections with A. abstrusus in cats. Regarding treatment, a single application of Advocate® reduced the worm burden, but it did not sufficiently clear the infection. In contrast, three monthly treatments were safe and highly efficacious against A. abstrusus.
Databáze: OpenAIRE
Externí odkaz: